Correspondence |

Interferon- γ Release Assay

Leonard M. Milstone, MD; Byron H. Waksman, MD
Arch Dermatol. 2012;148(1):133-134. doi:10.1001/archdermatol.2011.2077.
Text Size: A A A
Published online


Readers of a recent article published in the Archives about the usefulness of an interferon- γ release assay in diagnosing erythema induratum1 might like to put that work in historical and technical perspective. Many years ago, a medical student (L.M.M.), wondering why lymphocytes infiltrated virus-infected tissues, teamed up with an immunologist (B.H.W.) working in the emerging field of lymphokines. They hypothesized that sensitized lymphocytes challenged by a specific antigen might release an inhibitor of viral replication. Since tuberculin reactivity was a standard (and nonviral) manifestation of delayed-type hypersensitivity, they took lymphocytes from mice immunized with PPD (purified protein derivative, used in tuberculosis skin testing), challenged them in vitro with PPD, and found that those lymphocytes secreted an inhibitor of vesicular stomatitis virus growth.2 That secreted inhibitor eventually became known as interferon- γ, and the basics of that original test have been recapitulated in several interferon- γ release assays for tuberculosis.3

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles